1996
Commissioning of the German Center Biomaterial and Organ Replacement Stuttgart-Tübingen, BMOZ for short. An interdisciplinary center with partners from medicine and industry, it conducts research on, inter alia, absorbable membrane, i.e. a synthetic skin substitute.
1997
Launch of the BMBF project to develop a wound dressing for burns with funding that totals over four million German marks.
1998
![](https://polymedics.com/wp-content/uploads/2024/01/DITF_Luftbild_2014_nach_Vereinbarung.jpg)
V16, a new resorbable and highly porous membrane, the later SUPRATHEL®, fulfills its developers’ requirements. 1
1999
![](https://polymedics.com/wp-content/uploads/2024/01/gebaeudefassade_2014_1240x813_foto_Volker-Schrank.jpg)
V16 is used for the first time to treat burns at the Marienhospital in Stuttgart. The results are so impressive that the physicians feel it is irresponsible to continue treating burns conventionally.2
2000
“SUPRATHEL®“ secures worldwide patent and brand name protection.
2001
![](https://polymedics.com/wp-content/uploads/2024/01/Prospekte.jpg)
PolyMedics Innovations is founded, taking over the rights to SUPRATHEL®; the other participants are not in pursuing the project further.
2004
![](https://polymedics.com/wp-content/uploads/2024/01/Stand_2004.jpg)
CE approval for SUPRATHEL® for use in second-degree burns (2a and 2b) and in donor sites.
2005
SUPRATHEL® receives extended CE approval for use on mixed (second and third) degree. By the year’s end SUPRATHEL® has been used to treat over 1,000 patients.
2007
![](https://polymedics.com/wp-content/uploads/2024/01/Dr_Rapp.jpg)
At the year’s end over 3,000 patients have been treated with SUPRATHEL® and the product is in use in around 15 countries. In Germany, Austria, and Switzerland alone it is used consistently in over 120 clinics.
2008
SUPRATHEL® is launched in France and registered in Mexico. Over 4,000 people have now been treated with SUPRATHEL®.
2009
![](https://polymedics.com/wp-content/uploads/2024/01/Suprathel.jpg)
SUPRATHEL® secures 510k approval in the U.S.
2010
SUPRATHEL® receives South Korea’s KFDA approval. It is now manufactured in the company’s own clean room in Denkendorf.
2012
SUPRATHEL® receives market approval in Mexico.
2022
SUPRATHEL® is recognized by means of reimbursement coding as a synthetic skin substitute.
2022
![](https://polymedics.com/wp-content/uploads/2024/01/MDR.jpg)
SUPRATHEL® is granted MDR approval in Germany, the news arriving right on time as a “Christmas present”.
2023
![](https://polymedics.com/wp-content/uploads/2024/01/RKoch_DJI_0100-final_ganz-klein.jpg)
PolyMedics Innovations moves to new premises in Kirchheim/Teck. SUPRATHEL® is in use in nearly 40 countries around the world.
2023
![](https://polymedics.com/wp-content/uploads/2024/01/Herunterladen.jpg)
SUPRATHEL® receives market approval in Brazil.